Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo

 

Unsupported browser: Your browser does not meet modern web standards. See how it scores »

An illustration of the hemagglutinin protein (shown in yellow
and blue) on the H5 influenza virus H5, bound to a
neutralizing antibody (red).
Credit: William C. Hwang

Flu shots have to be reformulated every year, thanks to the constantly mutated virus. And the annual vaccine won’t protect against more deadly strains, like the H5N1 bird flu. But that may soon change: scientists have now developed antibody proteins that can neutralize different strains of the influenza virus, including the deadly H5N1 bird flu, the virus behind the 1918 epidemic, and common seasonal strains. These new antibodies target part of the virus that is shared between different strains and thus appears to be broadly effective. The research was published on Sunday in the journal Nature Structural & Molecular Biology.

According to an article in Nature,

The antibodies also give researchers clues about how to develop new vaccines. “This opens up the avenue of thinking about universal influenza vaccines, which has not been realistic before”, says Peter Palese, an influenza expert at Mount Sinai School of Medicine in New York who was not involved in the work.

A vaccine using this technology could theoretically be used to protect against various types of flu, as well as to treat the virus once a person is infected. Scientists who developed the antibodies say that they hope to have a candidate vaccine to test in humans within the next three years.

But not everyone is as optimistic about the possibilities. According to an article in the New York Times,

Henry L. Niman, a biochemist who tracks flu mutations, was skeptical, arguing that human immune systems would have long ago eliminated flu were the virus as vulnerable in one spot as this discovery suggested. Also, he noted, protecting the mice in the study took huge doses of antibodies, which are expensive and cumbersome to infuse.

[…]

The research began by screening a library of 27 billion antibodies he had created, looking for ones that take aim at the hemagglutinin “spikes” on the shells of flu viruses … The flu virus uses the lollipop-shaped hemagglutinin spike to invade nose and lung cells. There are 16 known types of spikes, H1 through H16.

The spike’s tip mutates constantly, which is why flu shots have to be reformulated each year. But the team found a way to expose the spike’s neck, which apparently does not mutate, and picked antibodies that clamped onto it. Once its neck is clamped, a spike can still penetrate a human cell, but it cannot unfold to inject the genetic instructions that take over the cell’s machinery to make more virus. The team then turned the antibodies into full-length immunoglobulins and tested them in mice.

2 comments. Share your thoughts »

Tagged: Biomedicine, vaccine, Flu, influenza, antibodies

Reprints and Permissions | Send feedback to the editor

From the Archives

Close

Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me